Results 171 to 180 of about 3,492,883 (216)

Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997-2026). [PDF]

Chin Med J (Engl)
Xie Z, Chen X, Gao R, Yang M, Han X, Sun Y, Shi Y.   +6 more
europepmc   +1 more source

BRAF^V600E patient derived colon cancer organoids identify biomarkers of response to EGFR and BRAF inhibition and replicate clinical data. [PDF]

J Exp Clin Cancer Res
Kotarac A, Osumi H, Malt A, Alp KM, Jarosch A, Werner J, Benary M, Neumann CCM, Yao R, Mertins P, Eils R, Beule D, Sers C, Keilholz U, Ishaque N, Stintzing S, Vecchione L.   +16 more
europepmc   +1 more source

Updates in the Management of EGFR-Mutated Non-small Cell Lung Cancer (NSCLC). [PDF]

Curr Oncol Rep
Vyas A, Jeon WJ, Alhushki S, Singhi E, Rous FA, Thawani R, Desai A.   +6 more
europepmc   +1 more source

GRIP-Lung: Generative Model of Response to Drug-Induced Perturbation in Lung Cancer. [PDF]

Int J Mol Sci
Fu Z, Li Y, Du Z, Zhang D, Liu L, Jin Q, Chen X, Xie H.   +7 more
europepmc   +1 more source

CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer. [PDF]

Cancer Res
Long SA, Todd H, Goodhart G, Chang WH, Amparo AM, Bridgens R, Dilly J, Park SJ, Beal RM, Shehadeh SM, Satyadi MA, Trivedi VK, Ackermann SE, Mukherjee R, Goodwin CM, Edwards AC, Stalnecker CA, Greis KD, Aguirre AJ, Hobbs GA, Bryant KL, Ahmad SA, Cox AD, Der CJ, Waters AM.   +24 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

[ 11 C]Erlotinib PET cannot detect acquired erlotinib resistance in NSCLC tumor xenografts in mice

Nuclear Medicine and Biology, 2017
[11C]Erlotinib PET has shown promise to distinguish non-small cell lung cancer (NSCLC) tumors harboring the activating epidermal growth factor receptor (EGFR) mutation delE746-A750 from tumors with wild-type EGFR. To assess the suitability of [11C]erlotinib PET to detect the emergence of acquired erlotinib resistance in initially erlotinib-responsive ...
Thomas Wanek, Kushtrim Kryeziu, Christine Pirker   +2 more
exaly   +4 more sources

CAF‐secreted COL5A2 activates the PI3K/AKT pathway to mediate erlotinib resistance in head and neck squamous cell carcinoma

Oral Diseases
OBJECTIVE To investigate the mechanisms behind acquired resistance to erlotinib in head and neck squamous cell carcinoma (HNSCC) with a focus on the role of cancer-associated fibroblasts (CAFs) and the PI3K/AKT signaling pathway.
Guo Yibo
exaly   +2 more sources

Abstract 5368: Role of spatially distinct tumor fibroblast in erlotinib resistance

Cancer Research, 2022
Metabolic reprogramming toward the hexosamine biosynthesis pathway (HBP), an understudied glucose pathway leading to O-glycosylation, is associated with poor survival in the lung adenocarcinoma (LUAD).
G. Bouchard, S. Plevritis
semanticscholar   +2 more sources

Combination treatment with erlotinib and ampelopsin overcomes erlotinib resistance in NSCLC cells via the Nox2-ROS-Bim pathway.

Lung Cancer, 2017
OBJECTIVES Erlotinib, a tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR), has been shown to have a dramatic effect in non-small cell lung cancer (NSCLC) patients with EGFR mutation. However, the presence of primary resistance or
Seung-Woo Hong, Nam-Sook Park, M. Noh, Ju A. Shim, Byul‐Nim Ahn, YeongSeok Kim, Daejin Kim, Hyun-Kyung Lee, D. Hur   +8 more
semanticscholar   +3 more sources

Click ferrocenyl-erlotinib conjugates active against erlotinib-resistant non-small cell lung cancer cells in vitro

Bioorganic Chemistry, 2022
Thanks to development of erlotinib and other target therapy drugs the lung cancer treatment have improved a lot in recent years. However, erlotinib-resistant lung cancer remains an unsolved clinical problem which demands for new therapeutics to be developed.
Bieganski P., Godel M., Riganti C., Kawano D. F., Kopecka J., Kowalski K.   +5 more
openaire   +2 more sources